Astec Lifescienc

Has Astec Lifescienc declared dividend?

Astec Lifesciences Ltd has declared a 15% dividend, amounting to ₹1.5 per share, with an ex-date of July 21, 2023. However, the dividend yield is 0%, and total returns over various periods show significant declines in stock price.

Astec Lifesciences Ltd has declared a 15% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 15%<BR>- Amount per share: 1.5<BR>- Ex-date: 21 Jul 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -26.09%, the dividend return was 0%, resulting in a total return of -26.09%.<BR><BR>Over the past year, the price return was -30.47%, the dividend return was 0%, leading to a total return of -30.47%.<BR><BR>In the 2-year period, the price return was -43.16%, with a dividend return of 0.11%, culminating in a total return of -43.05%.<BR><BR>For the 3-year period, the price return was -55.72%, the dividend return was 0.17%, resulting in a total return of -55.55%.<BR><BR>In the 4-year period, the price return was -42.55%, with a dividend return of 0.33%, leading to a total return of -42.22%.<BR><BR>Over the last 5 years, the price return was 8.85%, the dividend return was 0.74%, resulting in a total return of 9.59%.<BR><BR>Overall, while Astec Lifesciences Ltd has declared a dividend, the total returns over various periods indicate significant declines in price, with only modest positive returns in the longer term. The dividend yield remains at 0%, suggesting limited income generation from dividends relative to the stock price.

Who are the peers of the Astec Lifescienc?

Astec Lifescienc's peers include P I Industries, UPL, Bayer CropSci., and others. In terms of management risk, Astec Lifescienc is rated below average, with a 1-year return of -35.47%, the lowest among its peers.

Peers: The peers of Astec Lifescienc are P I Industries, UPL, Bayer CropSci., Sumitomo Chemi., Dhanuka Agritech, Heranba Inds, Dharmaj Crop, Shivalik Rasayan, and Best Agrolife.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bayer CropSci., Dhanuka Agritech, and P I Industries, while Good management risk is found at Sumitomo Chemi., Best Agrolife, and Heranba Inds. Average management risk is present at UPL, Dharmaj Crop, and the rest. Below Average management risk is noted at Astec Lifescienc and Shivalik Rasayan. In terms of Growth, Excellent growth is seen at P I Industries, while Average growth is found at Dharmaj Crop and the rest. Below Average growth is noted at UPL, Bayer CropSci., Sumitomo Chemi., Dhanuka Agritech, Heranba Inds, Astec Lifescienc, Shivalik Rasayan, and Best Agrolife. Capital Structure ratings show Excellent at Bayer CropSci., Sumitomo Chemi., and Dhanuka Agritech, while Good is seen at Heranba Inds and Dharmaj Crop. Average capital structure is noted at Astec Lifescienc and Best Agrolife, with Below Average at UPL and Shivalik Rasayan.<BR><BR>Return Snapshot: Dhanuka Agritech has the highest 1-year return at 32.65%, while Astec Lifescienc has the lowest at -35.47%, indicating a significant negative performance compared to its peers. Additionally, peers with negative six-month returns include Astec Lifescienc, Heranba Inds, and Best Agrolife.

Who are in the management team of Astec Lifescienc?

As of March 2023, the management team of Astec Lifescienc includes Ashok V Hiremath (Director), N B Godrej (Chairman), Balram Yadav (Director), Anurag Roy (Whole Time Director & CEO), and several independent directors, among others. The team consists of a mix of directors and key executive roles.

As of March 2023, the management team of Astec Lifescienc includes the following individuals:<BR><BR>1. Ashok V Hiremath - Director<BR>2. N B Godrej - Chairman (Non-Executive)<BR>3. Balram Yadav - Director<BR>4. Vijay Kashinath Khot - Independent Director<BR>5. Brahma Nand Vyas - Independent Director<BR>6. Tejashree Pradhan - Company Secretary & Compliance Officer<BR>7. Govindan Ramakrishna Rishinaradamangalam - Independent Director<BR>8. Dhekne Vasant Nandkumar - Independent Director<BR>9. Anjali Rajesh Gupta - Independent Director<BR>10. Anurag Roy - Whole Time Director & CEO<BR>11. Burjis Godrej - Director<BR><BR>This team encompasses a mix of directors, independent directors, and key executive roles.

What does Astec Lifescienc do?

Astec Lifesciences Ltd is a small-cap company that produces agrochemicals and pharmaceutical intermediates, reporting net sales of 1,195 Cr and a net loss of 161 Cr for March 2025. The company has a market cap of INR 2,067 Cr and a debt-to-equity ratio of 2.35.

Overview:<BR>Astec Lifesciences Ltd is a producer of agrochemicals and pharmaceutical intermediates, operating within the Pesticides & Agrochemicals industry and classified as a Small Cap company.<BR><BR>History:<BR>The company was incorporated in an unspecified year and has undergone no status changes. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,195 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: -161 Cr (Quarterly Results - Mar 2025)<BR>- Market cap: INR 2,067 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A (Loss Making)<BR>- Industry P/E: 40<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 2.35<BR>- Return on Equity: -57.40%<BR>- Price to Book: 8.80<BR><BR>Contact Details:<BR>Address: GodrejOne 3rd Fl Pirojshanagar, Vikhroli (E) Eastern Exp Highw Mumbai Maharashtra : 400079<BR>Tel: 91-22-25188010<BR>Email: astecinfo@godrejastec.com<BR>Website: http://www.astecls.com

Who are the top shareholders of the Astec Lifescienc?

The top shareholder of Astec Lifescienc is Godrej Agrovet Limited, with a 64.75% stake. Other shareholders include individual investors (19.62%), mutual funds (3.96%), and foreign institutional investors (0.25%), with Nippon Life India Trustee Ltd being the largest public shareholder at 2.35%.

The top shareholders of Astec Lifescienc include Godrej Agrovet Limited, which holds the largest stake at 64.75%. The company also has a diverse range of other shareholders, including individual investors who collectively own 19.62% of the shares. Additionally, mutual funds hold 3.96% across three schemes, while foreign institutional investors (FIIs) have a smaller stake of 0.25% through eight different entities. The highest public shareholder is Nippon Life India Trustee Ltd, which manages the Nippon India Small Cap Fund, holding 2.35%.

How big is Astec Lifescienc?

As of 24th July, Astec Lifesciences Ltd has a market capitalization of 2,028.00 Cr and reported net sales of 381.31 Cr with a net loss of 134.75 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Astec Lifesciences Ltd has a market capitalization of 2,028.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 381.31 Cr, while the sum of Net Profit for the same period reflects a loss of 134.75 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 234.75 Cr and Total Assets valued at 881.42 Cr.

How has been the historical performance of Astec Lifescienc?

Astec Lifescienc has experienced a significant decline in net sales and profitability, with losses increasing from a profit of 89.88 crore in March 2022 to a loss of 134.71 crore in March 2025, alongside a decrease in total assets and negative cash flow from operations.

Answer:<BR>The historical performance of Astec Lifescienc shows a declining trend in net sales and profitability over the past few years, culminating in significant losses in the most recent fiscal year.<BR><BR>Breakdown:<BR>Astec Lifescienc's net sales have decreased from 676.57 crore in March 2022 to 381.30 crore in March 2025, reflecting a downward trend in revenue generation. The total operating income followed a similar pattern, dropping from 676.57 crore in March 2022 to 381.30 crore in March 2025. The company's total expenditure, excluding depreciation, peaked at 551.91 crore in March 2023 but slightly decreased to 447.51 crore in March 2025. This resulted in an operating profit (PBDIT) that fell from 164.55 crore in March 2022 to a loss of 60.58 crore in March 2025. The profit before tax also turned negative, going from a profit of 121.13 crore in March 2022 to a loss of 140.99 crore in March 2025. Consequently, the profit after tax showed a similar decline, moving from a profit of 89.88 crore in March 2022 to a loss of 134.71 crore in March 2025. The company's total assets decreased from 979.41 crore in March 2023 to 881.42 crore in March 2025, while total liabilities also decreased from 974.93 crore to 881.42 crore during the same period. Cash flow from operating activities turned negative in March 2025, indicating challenges in generating cash from core operations. Overall, Astec Lifescienc has faced significant financial difficulties, leading to substantial losses and a decline in key financial metrics over the past few years.

Is Astec Lifescienc technically bullish or bearish?

As of November 21, 2025, the technical trend for Astec Lifesciences is mildly bearish with mixed signals across various indicators, suggesting caution in the current market environment.

As of 21 November 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish with weak strength. Key indicators include a bearish MACD on the weekly timeframe, a mildly bullish MACD on the monthly, and a mildly bearish moving average on the daily. The RSI is bearish on the weekly and shows no signal on the monthly. While the Bollinger Bands indicate bullishness on the weekly, they are mildly bearish on the monthly. The KST remains bearish across both timeframes, and Dow Theory shows mildly bullish on the weekly but mildly bearish on the monthly. Overall, the mixed signals suggest caution in the current market environment for Astec Lifescienc.

When is the next results date for Astec Lifesciences Ltd?

Astec Lifesciences Ltd will announce its results on January 30, 2026.

Astec Lifesciences Ltd is scheduled to declare its results on January 30, 2026.

Are Astec Lifesciences Ltd latest results good or bad?

Astec Lifesciences Ltd's latest results show strong revenue growth of 32.88% year-on-year, but the company reported a net loss of ₹15.70 crores, marking nine consecutive quarters of losses, which raises concerns about its sustainability and reflects bearish market sentiment. Overall, the results are more concerning than encouraging.

Astec Lifesciences Ltd's latest results present a mixed picture. On one hand, the company reported a significant revenue growth of 32.88% year-on-year, reaching ₹124.72 crores, and a remarkable sequential increase of 69.18% from the previous quarter. This suggests a recovery in demand for its products, which is a positive sign.<BR><BR>However, the company continues to face serious challenges, as it posted a net loss of ₹15.70 crores for the quarter, which is a 61.12% increase in losses compared to the same period last year. This marks nine consecutive quarters of losses, raising concerns about the sustainability of its business model. The operating margin improved to 3.20%, but this is still far below historical levels and indicates ongoing profitability issues.<BR><BR>Additionally, the stock has underperformed significantly, with a one-year decline of 42.46%, contrasting sharply with the Sensex's gain of 7.18%. The market sentiment appears bearish, with institutional investors largely retreating from the stock, further reflecting a lack of confidence in its recovery prospects.<BR><BR>In summary, while there are signs of revenue recovery, the persistent losses and deteriorating financial metrics suggest that the overall results are more concerning than encouraging.

Should I buy, sell or hold Astec Lifesciences Ltd?

Why is Astec Lifesciences Ltd falling/rising?

As of 17-Mar, Astec Lifesciences Ltd's stock price is rising to Rs 585.00, driven by increased investor interest and positive financial results after a period of decline. However, the stock's long-term fundamentals remain weak, indicating potential risks.

As of 17-Mar, Astec Lifesciences Ltd's stock price is rising, currently at Rs 585.00, reflecting an increase of Rs 6.1 or 1.05%. This rise can be attributed to several factors. Notably, the stock has outperformed its sector by 0.73% today and has experienced a trend reversal, gaining after two consecutive days of decline. Additionally, the stock reached an intraday high of Rs 591.1, indicating positive momentum.<BR><BR>Investor participation has also increased, with delivery volume rising by 180.83% compared to the 5-day average, suggesting heightened interest in the stock. Furthermore, the company recently declared positive results for December 2025 after six consecutive quarters of negative performance, showcasing a significant growth in net sales by 32.88% to Rs 124.72 crore. <BR><BR>However, it is important to note that despite the current rise, the stock has demonstrated weak long-term fundamental strength, with a -189.76% CAGR growth in operating profits over the last five years and a high debt-to-EBITDA ratio of 9.40 times. This indicates potential risks that could affect future performance. Nonetheless, the immediate factors contributing to the stock's rise include improved investor sentiment and recent positive financial results.

Why is Astec Lifesciences Ltd falling/rising?

As of 18-Mar, Astec Lifesciences Ltd's stock price is rising to Rs 592.00, reflecting a 1.05% increase. Despite this short-term gain, the stock has significantly underperformed over the long term, indicating caution for investors.

As of 18-Mar, Astec Lifesciences Ltd's stock price is rising, currently at Rs 592.00, reflecting a change of 6.15 (1.05%) upward. This increase follows a two-day consecutive gain, where the stock has risen by 2.26%. Additionally, the stock reached an intraday high of Rs 608.95, marking a 3.94% increase during the trading session. <BR><BR>Despite this recent uptick, the stock has underperformed against its sector by 0.58% today and has shown a significant decline over longer periods, including a 16.06% drop year-to-date and a 51.84% decrease over the past three years. The company recently reported positive results for December 2025 after six consecutive negative quarters, which may have contributed to the current rise in stock price. Key indicators such as the highest operating profit to interest ratio at 0.56 times and the lowest debt-equity ratio at 0.89 times suggest some improvement in financial health.<BR><BR>However, the overall long-term outlook remains weak, with a -189.76% CAGR growth in operating profits over the last five years and a high debt to EBITDA ratio of 9.40 times, indicating challenges in servicing debt. Furthermore, institutional investor participation has decreased by 0.8% in the previous quarter, which may reflect a lack of confidence in the stock's long-term performance. <BR><BR>In summary, while Astec Lifesciences Ltd is experiencing a short-term rise in stock price due to recent positive financial results and increased investor participation, the broader context of consistent underperformance and weak long-term fundamentals suggests caution for investors.

Why is Astec Lifesciences Ltd falling/rising?

As of 19-Mar, Astec Lifesciences Ltd's stock is at Rs 568.00, down 4.64%, with significant declines over various periods and underperformance compared to the Sensex. The stock is near its 52-week low, trading below moving averages, and showing weak long-term fundamentals, contributing to its bearish trend.

As of 19-Mar, Astec Lifesciences Ltd's stock price is falling, currently at Rs 568.00, reflecting a decrease of Rs 27.65 or 4.64%. This decline is evident in the stock's performance over various periods, with a 1-week drop of 9.46% and a 1-month decrease of 11.44%. Year-to-date, the stock has fallen by 19.46%, significantly underperforming the benchmark Sensex, which has only decreased by 12.92% during the same period.<BR><BR>Today's trading activity shows that the stock is close to its 52-week low, just 2.22% away from Rs 555.4. It has also underperformed its sector by 2.43% today, indicating a broader weakness in the market for pesticides and agrochemicals, which has fallen by 2.2%. The stock has experienced a trend reversal, having fallen after two consecutive days of gains, and it touched an intraday low of Rs 563, marking a decline of 5.48%.<BR><BR>Moreover, Astec Lifesciences Ltd is trading below its moving averages across multiple time frames (5-day, 20-day, 50-day, 100-day, and 200-day), which typically signals a bearish trend. Although there has been a slight increase in delivery volume, rising by 11.55% against the 5-day average, the overall liquidity remains low, with only 2% of the 5-day average traded value.<BR><BR>The company's long-term fundamentals are weak, highlighted by a staggering -189.76% CAGR growth in operating profits over the last five years and a high Debt to EBITDA ratio of 9.40 times, indicating a low ability to service debt. Furthermore, institutional investors have reduced their stake by 0.8% in the last quarter, reflecting a lack of confidence in the company's prospects. Overall, these factors contribute to the stock's current downward trajectory.

Why is Astec Lifesciences Ltd falling/rising?

As of 20-Mar, Astec Lifesciences Ltd's stock price is at 562.00, reflecting a decline of 3.7 (-0.65%). The stock has significantly underperformed against the benchmark, with a year-to-date drop of 20.31% and is trading close to its 52-week low, indicating weak investor confidence and bearish trends.

As of 20-Mar, Astec Lifesciences Ltd's stock price is falling, currently at 562.00, which reflects a decrease of 3.7 (-0.65%). The stock has been underperforming significantly against the benchmark, with a 1-week decline of 10.00% compared to a mere 0.04% drop in the Sensex. Over the past month, the stock has decreased by 11.61%, while the Sensex fell by 10.00%. Year-to-date, Astec Lifesciences has seen a decline of 20.31%, compared to a 12.54% drop in the benchmark.<BR><BR>The stock is also close to its 52-week low, just 1.17% away from Rs 555.4, indicating a lack of upward momentum. Performance today shows that it has underperformed its sector by 2.25%, and it has experienced consecutive falls for the last two days, totaling a decline of 5.65%. Furthermore, the stock is trading below all its moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), which typically signals a bearish trend.<BR><BR>Investor participation has also decreased, with delivery volume on 19 March falling by 51.29% compared to the 5-day average, suggesting waning interest from investors. Additionally, institutional investors have reduced their stake by 0.8% over the previous quarter, indicating a lack of confidence in the stock's future performance.<BR><BR>Despite some positive results reported in December 2025, such as a 32.88% growth in net sales and the lowest debt-equity ratio at 0.89 times, the long-term fundamentals remain weak. The company has experienced a staggering -189.76% CAGR growth in operating profits over the last five years, coupled with a high debt-to-EBITDA ratio of 9.40 times, which raises concerns about its ability to service debt. This combination of factors contributes to the stock's current downward trajectory.

Which are the latest news on Astec Lifescienc?

Which are the latest news on Astec Lifescienc?

Which are the latest news on Astec Lifescienc?